Download Files:

PZ703b

SKU HY-115718-1 mg Category Tags , ,

$1,400$6,800

Products Details

Product Description

– PZ703b is a Bcl-xl PROTAC degrader that induces apoptosis and inhibits cancer cell proliferation. PZ703b can be used for the research of bladder cancer research[1][2].

Web ID

– HY-115718

Storage Temperature

– -20°C (Powder, protect from light)

Shipping

– Blue Ice

Applications

– Cancer-programmed cell death

Molecular Formula

– C80H102ClF3N10O11S4

References

– [1]Pal P, et al. Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition. J Med Chem. 2021 Oct 14;64(19):14230-14246.|[2]Yi Xu, et al. Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway. Biochem Biophys Res Commun. 2022 Oct 1;623:120-126.

CAS Number

– 2471970-56-4

Molecular Weight

– 1600.43

Compound Purity

– 98.47

SMILES

– ClC1=CC=C(C=C1)C2=C(C[C@](CNC(CCCCCCCCC(N[C@H](C(N3C[C@@H](C[C@H]3C(N[C@@H](C)C4=CC=C(C=C4)C5=C(N=CS5)C)=O)O)=O)C(C)(C)C)=O)=O)(CC2)C)CN6CCN(CC6)C7=CC=C(C=C7)C(NS(C8=CC(S(=O)(C(F)(F)F)=O)=C(C=C8)N[C@H](CCN9CCOCC9)CSC%10=CC=CC=C%10)(=O)=O)=O

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)

Target

– Bcl-2 Family;PROTACs

Isoform

– Bcl-xL;von Hippel-Lindau (VHL)

Pathway

– Apoptosis;PROTAC

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.